Vnitr Lek 2023, 69(2):119-127 | DOI: 10.36290/vnl.2023.019

Pain treatment options for osteoarthritis

Olga Šléglová
Revmatologický ústav, Praha

Osteoarthritis is one of the most common diseases of the joints and spine and is characterized by degenerative changes starting in the cartilage. Joint changes cause pain, stiffness, swelling, and a loss of normal joint function. Several international recommendations address the choice of treatment methods for osteoarthritis. However, because there is still no effective causal treatment leading to a remission of the disease, this is a complex issue. Even the possibilities of effective but safe treatment of pain, which is the most common problem accompanying osteoarthritis, are very limited. All current international recommendations for the treatment of osteoarthritis agree on the crucial role of non-pharmacological treatment and the choice of a comprehensive approach to the treatment of osteoarthritis. Pharmacological treatment includes non-opioid analgesics, opioids, symptomatic slow-acting osteoarthritis drugs, or intra-articular corticosteroids. A new trend is to maximize the potential of existing analgesics by combining them. Using drugs from different classes with complementary mechanisms of action provides a better opportunity for effective analgesia at reduced doses of individual agents. The use of fixed combinations is also advantageous.

Keywords: analgesics, intra‑articular corticosteroids, non‑steroidal antirheumatic drugs, osteoarthritis, symptomatic slow‑acting drugs for osteoarthritis.

Accepted: March 23, 2023; Published: March 30, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šléglová O. Pain treatment options for osteoarthritis. Vnitr Lek. 2023;69(2):119-127. doi: 10.36290/vnl.2023.019.
Download citation

References

  1. Cisternas MG, Murphy L, Sacks JJ, Solomon DH, et al. Alternative Methods for Defining Osteoarthritis and the Impact on Estimating Prevalence in a US Population‑Based Survey. Arthritis Care Res (Hoboken). 2016;68(5):574-580. Go to original source... Go to PubMed...
  2. Pavelka K, Olejárová M. Osteoatróza. In: Pavelka K, Vencovský J, Horák P, et al. Revmatologie. Maxdorf, Praha 2018:556-594. ISBN 978-80-7345-583-5.
  3. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220-233. Go to original source...
  4. Bannura RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non‑surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage. 2019;27:1578-1589. Go to original source...
  5. Bruyere O, Honvoa G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49:337-350. Go to original source...
  6. Kloppenburg M, Kroon FPB, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum, DiS. 2019;78:16-24. Go to original source... Go to PubMed...
  7. Pavelka K. Doporučení České revmatologické společnosti pro léčbu osteoartrózy kolenních, kyčelních a ručních kloubů. Čes Revmatol. 2012;3:138-156.
  8. Fernandes L, Hagen KB, Bijlsma JWJ, et al. EULAR recommendations for the non‑pharmacological core management of hip and knee osteoarthritis. Ann Rheum, DiS. 2013;72:1125-1135. Go to original source... Go to PubMed...
  9. Forejtová S. Systémová nesteroidní antirevmatika. In: Pavelka K, Vencovský J, Šenolt L, et al. Farmakoterapie revmatických onemocnění. Maxdorf, Praha 2017: 33-41. ISBN 978-80-7345-537-8.
  10. Derry S, Moore RA, Gaskell H, McIntyre M, Wiffen PJ. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015; CD007402. Go to original source...
  11. Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2012;9:CD007400. Go to original source...
  12. Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016; CD007400. Go to original source...
  13. Rannou F, Pelletier JP, Martel‑Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: evidence from real‑life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4Suppl):S18-21. Go to original source...
  14. Lejčko J, Kozák J, Fricová J, et al. Metodické pokyny pro farmakoterapii bolesti. Bolest. 2016;19 suppl.1:1-27.
  15. Toupin AK, Bisaillon J, Welch V, et al. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2019;27:CD005522.
  16. Pergolizzi JV jr., van de Laar M, Langford R, et al. Tramadol/paracetamol fixed‑dose combination in the treatment of moderate to severe pain. J Pain Res. 2012;5:327-346. Go to original source... Go to PubMed...
  17. Moore RA, Gay‑Escoda C, Figueiredo R, et al. Dexketoprofen/tramadol: randomised double‑blind trial and confirmation of empirical theory of combination analgesics in acute pain. J Headache Pain. 2015;16:541-8. Go to original source...
  18. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long‑term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162:276-86. Go to original source...
  19. Dowell D, Haegerich TM, Choi R. CDC Gudelines for prescribing opioids for chronic pain. United States, 2016. Recommendations and reports. 2016;65(1):1-49. Go to original source...
  20. Wang ZY, Shi SY, Li SJ, et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta‑analysis of randomized controlled trials. Pain Med. 2015;16(7):1373-1385. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.